Pharmacy | Home | MIMS Malaysia

Malaysia
Search
Sign In

Pharmacy

Pharmacy

Home News Conferences Special Reports Multimedia

Nivolumab improves survival in Asians with pretreated advanced NSCLC

Jairia Dela Cruz, 5 hours ago

Nivolumab significantly prolongs survival in East Asian patients with advanced nonsmall cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy when compared with docetaxel, according to data from the CheckMate 078 trial.

Swallowed topical steroids may favourably alter disease course of EoE patients

Yesterday

Use of swallowed topical corticosteroids in the maintenance setting appears to increase the probability of achieving complete remission in eosinophilic esophagitis (EoE) as compared with nonuse, a study has found.

SGLT2 inhibitor provides greater weight loss benefits than metformin, gliptins

2 days ago

In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.

Treating vitamin D deficiency may help prevent COPD attacks

Pearl Toh, 3 days ago

Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).

Time and size key to functional recovery in thrombectomy for large-core stroke

Pearl Toh, 3 days ago

A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.

Comprehensive genomic profiling in oncology – from vision to reality

Dr. Jeffrey Ross, Dr. Rohit Lal, Prof. Alwin Krämer, Dr. Rebecca Dent, Prof. Rafal Dziadziuszko, 24 Jan 2019

Comprehensive genomic profiling (CGP) has emerged as a key driving force behind personalized cancer care. With the wealth of data available with CGP, medical oncologists now have in their armamentarium a tool that could enable them to provide patients with the optimum treatment. At a Roche Foundation Medicine-sponsored symposium held at the 2018 European Society of Medical Oncology (ESMO) Congress in Munich, Germany, a panel of experts reviewed key data on CGP, with a focus on the treatment of advanced cancers.

Real-world management of stable coronary artery disease

Dr. Choo Gim Hooi, Assoc Prof. Pattarapong Makarawate, Dr. Krisada Sastravaha, 17 Dec 2018

Coronary artery disease (CAD) is a leading cause of mortality and morbidity globally and its burden is expected to increase due to the rising prevalence of risk factors such as hypertension, diabetes, and dyslipidaemia. In conjunction with the 23rd ASEAN Federation of Cardiology Congress held in Bangkok, Thailand, Menarini organized a lunch symposium and product theatre to discuss the significance of optimal medical therapy (OMT) in the management of stable CAD, with a focus on the role of ranolazine (Ranexa^®).

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

01 Nov 2018

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Optimizing CV outcomes with evolocumab

Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

Time and size key to functional recovery in thrombectomy for large-core stroke

Pearl Toh, 15 Feb 2019

Cilostazol + aspirin/clopidogrel may reduce recurrent ischaemic stroke risk

Roshini Claire Anthony, 13 Feb 2019

The addition of the phosphodiesterase 3 inhibitor cilostazol to either aspirin or clopidogrel reduced the risk of recurrent stroke among patients at high risk of recurrence following a non-cardioembolic ischaemic stroke, according to the CSPS.com* study conducted in Japan.

Prostate cancer biomarker research gains momentum, but challenges remain

Jackey Suen, 30 Jan 2019

Recent research has revealed various potential biomarkers for metastatic castration-resistant prostate cancer (mCRPC), but several challenges remain in fully utilizing them in clinical practice.

Post-marketing data reaffirm vedolizumab safety in real world

Pearl Toh, 28 Jan 2019

The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.

Low rate of C. difficile infection in UC patients on tofacitinib

Roshini Claire Anthony, 28 Jan 2019

The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.

Older age a risk factor for AEs during ulcerative colitis treatment

Elaine Soliven, 23 Jan 2019

Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.

Ferric carboxymaltose preferred over other iron compounds for IDA in IBD

Audrey Abella, 22 Jan 2019

Ferric carboxymaltose (FCM) remains the most effective intravenous (IV) iron formulation as monotherapy followed by iron sucrose/saccharate (IS) and presented a better safety profile with fewer adverse events (AEs) in patients with inflammatory bowel disease (IBD) with iron deficiency anaemia (IDA), according to an updated meta-analysis presented at AIBD 2018.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!